What Qtern 5/10 Treats: Main Uses and Benefits

Qtern 5/10 is a prescription treatment intended to improve blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). The medication is generally used as an adjunct to a plan of diet and exercise when other initial therapies, such as metformin or monotherapy with one of Qtern's components, have not provided adequate glycemic management.

The primary benefit is helping to manage elevated blood glucose levels. Better control of blood sugar is important for reducing the risk of long-term T2DM complications, including effects on the kidneys, nerves, and eyes.

Additionally, Qtern 5/10 is indicated for use in adults with T2DM and established cardiovascular disease to help lower the risk of cardiovascular death and hospitalization for heart failure. Talk to your healthcare provider to understand if this additional benefit is relevant to your specific health profile.

---

Quick Fact: Relief for Elevated Blood Glucose

Who Can and Cannot Use Qtern 5/10?

This medication is approved for use in adults aged 18 and older with Type 2 Diabetes Mellitus to help improve blood sugar control.

Contraindications (Do Not Use)

Qtern 5/10 is contraindicated (must not be used) in patients who have:

• A history of a serious hypersensitivity reaction (severe allergy) to either dapagliflozin, saxagliptin, or any other medication in the same drug classes (DPP-4 inhibitors or SGLT2 inhibitors).
• Moderate to severe renal impairment (eGFR persistently below 45 mL/min/1.73 m^2), End-Stage Renal Disease (ESRD), or are on dialysis.

Eligibility Restrictions and Special Considerations

Use is not recommended or requires special caution in the following populations:

Population/Condition	Eligibility Status/Restriction
Renal Function	Do not initiate if eGFR is below 60 mL/min/1.73 m^2.
Severe Hepatic Impairment	Not recommended for use.
Type 1 Diabetes Mellitus	Not indicated for treatment.
Diabetic Ketoacidosis (DKA)	Not indicated for treatment.
Pregnancy	Not recommended; discontinue treatment if pregnancy is detected.
Lactation (Breastfeeding)	Not recommended.
Active Bladder Cancer	Should not be used; use with caution if there is a prior history.
Aged 75 years and older (EMA)	Initiation is not recommended; use caution in elderly patients due to risk of volume depletion.

This combination medicine is strictly intended for adults with Type 2 Diabetes and its eligibility is strongly dependent on the patient's renal function, with specific eGFR thresholds defining contraindications and restrictions.

Interactions with other medicines and products

The official regulatory profile for Qtern 5/10 interactions is strictly defined by constraints concerning both pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms.

---

Formal Regulatory Restrictions

The combination is formally contraindicated with strong CYP3A4/5 inhibitors, including medicines such as ketoconazole, atazanavir, and ritonavir. This is classified as a significant pharmacokinetic interaction because the inhibition of the CYP3A4/5 enzyme system results in a substantial increase in the plasma concentration of the saxagliptin component.

---

Pharmacodynamic Interactions

Co-administration with other blood-glucose-lowering agents, specifically insulin or insulin secretagogues, leads to an additive pharmacodynamic effect that carries an increased risk of hypoglycemia. A separate additive interaction occurs with diuretics (such as loop or thiazide types), which increases the risk of volume depletion and symptomatic hypotension. This volume-related risk is officially noted as more pronounced in elderly patients and individuals with impaired renal function. The product is also documented to lower the amount of lithium in the blood. There are no mandatory timing separation rules documented in the regulatory labeling, and the medicine may be taken with or without food.

Qtern 5/10 is a fixed-dose combination containing two active pharmacological agents with distinct mechanistic targets: saxagliptin and dapagliflozin.

Saxagliptin functions as a selective, competitive, and reversible inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). This interaction prevents the rapid enzymatic degradation of endogenous incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The resulting elevation of active incretin concentrations enhances the glucose-dependent release of insulin from pancreatic beta-cells and simultaneously suppresses glucagon secretion from pancreatic alpha-cells.

Dapagliflozin operates as a selective, reversible inhibitor of the sodium-glucose co-transporter 2 (SGLT2). SGLT2 is predominantly located on the brush border of the proximal renal tubule. By inhibiting SGLT2, dapagliflozin prevents the reabsorption of filtered glucose in the kidney, which lowers the renal threshold for glucose. This mechanism results in a sustained, insulin-independent increase in urinary glucose excretion (glucosuria). The osmotic effect of this process subsequently induces an osmotic diuresis and natriuresis, leading to a decrease in circulating plasma volume and associated reduction in systemic arterial pressure.

Official Administration Guidelines for Qtern 5/10

Qtern 5/10 is an oral tablet containing 5 mg of saxagliptin and 10 mg of dapagliflozin. This medicine is for use only in adults.

---

Dosing and Timing

The recommended dose is one Qtern 5/10 tablet taken once daily.

• Route: The tablet is taken orally.
• Preparation: Swallow the tablet whole. Do not crush, cut, or chew the tablet.
• Timing: The medicine can be taken at any time of day, but it is recommended to take it at the same time each day for consistency. It may be taken with or without food.

Missed Dose Instructions

If a dose is missed, the course of action is determined by the time remaining until the next scheduled dose:

• If it is 12 hours or more until the next scheduled dose, the missed dose should be taken immediately.
• If it is less than 12 hours until the next scheduled dose, the missed dose should be skipped, and the next dose taken at the usual time.
• Do not take a double dose to make up for a forgotten dose.

---

Procedural Conditions

The patient's renal function (estimated glomerular filtration rate or eGFR) is assessed before initiating therapy and periodically thereafter. Treatment should not be initiated if the eGFR is below 60 mL/min/1.73 m^2. Treatment must also not be coadministered with strong CYP3A4/5 inhibitors.

Research Evidence / Overview of Studies for Qtern 5/10

---

Evidence for Use in Blood Sugar Control (Glycaemic Management)

Research has explored how this medication was evaluated in studies related to blood sugar biomarker levels primarily involving short-term randomized controlled trials (RCTs). The trials typically monitored adult patients with Type 2 diabetes who were involved in research scenarios evaluating their blood sugar biomarker levels. Researchers monitored key biomarkers such as Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG), and also monitored body weight as an outcome measured during the study period.

The existing studies provide insight into short-term changes in these biomarkers. However, the available data for the fixed-dose combination (FDC) tablet itself provides limited information for long-term outcomes regarding the maintenance of blood sugar biomarker levels. The follow-up durations were limited for the pivotal FDC efficacy studies, meaning longer-term effects are not fully established.

---

Evidence for Cardiovascular and Renal Outcomes

Longer-term research has been conducted, primarily using the individual components of Qtern, to examine outcomes related to major complications, specifically the heart and kidneys. These evaluations are known as Cardiovascular Outcomes Trials (CVOTs). The studies monitored the occurrence of major cardiac events, such as cardiovascular death and hospitalization for heart failure.

Data related to the Dapagliflozin component of Qtern was observed in studies examining the occurrence of cardiovascular death and hospitalization for heart failure. However, a separate CVOT for the Saxagliptin component described patterns associated with a greater rate of hospitalization for heart failure observed in that trial. It is important to note that the FDC tablet was not the study drug in these long-term CVOTs; the long-term outcomes of combining the two components on major cardiac events remain an area where certainty remains low because data are still emerging.

---

What Remains Uncertain About the Research

Research contributes to the broader evidence landscape, but it also highlights what is still uncertain. The primary uncertainty involves the long-term outcomes of the FDC because follow-up durations were limited for the specific combination tablet. Comparative evidence is lacking for the two drugs taken together over many years, as the long-term cardiovascular research examined the individual components, not the combination itself. Subgroup findings for many specific patient groups remain uncertain.

Key Studies & References

1. European Medicines Agency (EMA) Community Register: Qtern (Dapagliflozin/Saxagliptin) Annexes

Common questions about Qtern 5/10 (FAQ)

Q: How is Qtern 5/10 different from taking the two components separately?

Regulatory documents indicate that the fixed-dose combination (FDC) tablet was shown to be bioequivalent to taking the two components, saxagliptin and dapagliflozin, as separate pills at the same dose. This means the body is expected to absorb and process the components similarly. The FDC tablet simply offers the benefit of simplifying the treatment by combining the two medicines into a single pill.

Q: How long after starting Qtern 5/10 might I begin to notice a change in blood sugar results?

Pharmacokinetic studies cited in official documents show that the active components in Qtern 5/10 are absorbed rapidly into the bloodstream, reaching their highest concentration within a few hours of administration. While the active components are absorbed rapidly, the measurable effect on long-term blood sugar markers is typically assessed over several weeks of consistent use.

Q: Is Qtern 5/10 associated with potential changes in body weight?

Official information indicates that clinical trials monitored body weight as an outcome measure during the study period. The dapagliflozin component functions by promoting the urinary excretion of glucose, which is equivalent to a caloric loss.

Q: Can Qtern 5/10 cause frequent urination or increase the volume of urine?

The mechanism of action for the dapagliflozin component involves increasing the amount of glucose that is passed out through the urine. This action, known as osmotic diuresis, results in an increased amount of urine being produced by the body.

Q: What are the signs of dehydration that may be related to taking Qtern 5/10?

Official documentation notes that the drug is associated with a risk of volume depletion, or dehydration, and related reactions such as symptomatic hypotension (low blood pressure). To manage this risk, regulatory documents advise that blood pressure, volume status, and certain lab tests may be monitored during therapy.

Q: What are the symptoms of a potentially rare condition called ketoacidosis when taking Qtern 5/10?

Regulatory documents list symptoms that may be experienced with diabetic ketoacidosis (DKA), which is a rare but serious condition. These symptoms may include nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness. DKA is noteworthy as it can occur even when blood sugar levels are not significantly high.

Q: What is the risk of developing a severe genital infection (Fournier’s gangrene) with this drug?

Regulatory warnings mention the risk of a rare, serious infection called necrotizing fasciitis of the perineum, or Fournier’s gangrene. Official warnings note that symptoms such as pain, tenderness, redness, or swelling in the genital or perineal area, particularly if accompanied by fever or general malaise, are noted in regulatory documents as requiring attention.

Q: Does Qtern 5/10 increase the risk of developing joint pain (arthralgia)?

Regulatory documents contain a warning about the potential for severe and disabling joint pain (arthralgia) associated with the DPP-4 inhibitor class of medicines, which includes the saxagliptin component of Qtern 5/10. Regulatory documents advise considering the drug as a possible cause when severe joint pain is reported.

Q: Can Qtern 5/10 affect long-term kidney function?

Official regulatory documents mandate the assessment of kidney function (eGFR) before starting therapy and periodically during treatment. Warnings cite the potential for Acute Kidney Injury and the medicine is restricted or contraindicated based on specific kidney function thresholds. The dapagliflozin component has been the subject of studies that examined its effects on factors related to chronic kidney disease progression.

Q: Has Qtern 5/10 been studied regarding a potential effect on cardiovascular outcomes?

Long-term research, known as Cardiovascular Outcomes Trials (CVOTs), has been conducted on the individual components of Qtern 5/10. A separate CVOT for the saxagliptin component described patterns associated with a greater rate of hospitalization for heart failure observed during that trial.

Q: What official clinical trials support the use of Qtern 5/10 for improving blood sugar control?

The regulatory approval of the combination was supported by evidence from specific Phase 3 efficacy and safety studies. These trials, which include studies identified by codes such as CV181168 and MB1021029, evaluated the drug's effect on blood sugar markers in adult patients with Type 2 diabetes.

Q: Are there general warnings about consuming alcohol while taking Qtern 5/10?

Regulatory documents list factors such as alcohol abuse that may increase the risk of developing diabetic ketoacidosis. Alcohol abuse is listed as a factor that may be considered before initiation of therapy.

Q: Are there any documented interactions between Qtern 5/10 and medications like Lithium?

Official documentation notes that the drug may result in a lowering of the amount of lithium in the blood. The interaction may require the monitoring of lithium levels.

Q: Are there any food-related restrictions while taking Qtern 5/10?

Official regulatory documents state that the medicine can be taken with or without food. No specific food restrictions are mandated in the official labeling for this medication.

Official Storage and Disposal Requirements

Qtern tablets must be stored and handled according to mandated regulatory conditions to ensure product stability and safety.

Storage Requirement	Official Condition
Temperature	Store at Controlled Room Temperature, 68 F to 77 F (20 C to 25 C) [FDA/DailyMed].
Protection	Keep in the container it came in, tightly closed, away from excess heat, moisture, and freezing [MedlinePlus].
Child Safety	Keep out of the reach of children at all times [FDA/DailyMed].

Unused or expired Qtern should be disposed of via a drug take-back program, which is the preferred method according to FDA guidelines. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before disposal in the household trash. The tablets are not on the FDA's flush list and must not be flushed down the toilet.